254 related articles for article (PubMed ID: 35818841)
1. The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.
Akari S; Nakamura T; Furusawa K; Miyazaki Y; Kario K
J Clin Hypertens (Greenwich); 2022 Aug; 24(8):1068-1075. PubMed ID: 35818841
[TBL] [Abstract][Full Text] [Related]
2. Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Honda M; Horiuchi H; Torii T; Nakajima A; Iijima T; Murano H; Yamanaka H; Ito S
BMC Pediatr; 2021 Dec; 21(1):581. PubMed ID: 34922491
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
5. Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan.
Kurajoh M; Akari S; Nakamura T; Ihara Y; Imai T; Morioka T; Emoto M
Front Pharmacol; 2024; 15():1230562. PubMed ID: 38292940
[No Abstract] [Full Text] [Related]
6. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
[TBL] [Abstract][Full Text] [Related]
7. Treatment for hyperuricemia and gout in Japan: Aspect of prescription and duration.
Zhang D
J Clin Hypertens (Greenwich); 2022 Aug; 24(8):1076-1078. PubMed ID: 35818832
[No Abstract] [Full Text] [Related]
8. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
[TBL] [Abstract][Full Text] [Related]
9. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
Hakoda M; Kasagi F
Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
[No Abstract] [Full Text] [Related]
10. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
[No Abstract] [Full Text] [Related]
11. [Gout and cardiovascular risk].
Němec P
Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
[TBL] [Abstract][Full Text] [Related]
12. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
13. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
[TBL] [Abstract][Full Text] [Related]
14. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
15. Critical revision of the medical treatment of gout in Brazil.
Azevedo VF; Lopes MP; Catholino NM; Paiva EDS; Araújo VA; Pinheiro GDRC
Rev Bras Reumatol Engl Ed; 2017; 57(4):346-355. PubMed ID: 28743362
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
17. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
18. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Bakris GL; Doghramji PP; Keenan RT; Silber SH
Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
[TBL] [Abstract][Full Text] [Related]
19. Gout and the Prevalence of Dementia: A Nationwide Population-Based Study.
Sung W; Kwon HS; Park Y; Kim SH; Park S; Kang DR; Choi H
J Alzheimers Dis; 2023; 96(1):343-349. PubMed ID: 37781802
[TBL] [Abstract][Full Text] [Related]
20. Why focus on uric acid?
Johnson RJ
Curr Med Res Opin; 2015; 31 Suppl 2():3-7. PubMed ID: 26414730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
